6.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RLAY Giù?
Forum
Previsione
Precedente Chiudi:
$6.61
Aprire:
$6.7
Volume 24 ore:
2.04M
Relative Volume:
1.07
Capitalizzazione di mercato:
$1.12B
Reddito:
$25.55M
Utile/perdita netta:
$-341.97M
Rapporto P/E:
-2.325
EPS:
-2.8
Flusso di cassa netto:
$-304.44M
1 W Prestazione:
-3.98%
1M Prestazione:
+57.63%
6M Prestazione:
+149.43%
1 anno Prestazione:
-4.26%
Relay Therapeutics Inc Stock (RLAY) Company Profile
Nome
Relay Therapeutics Inc
Settore
Industria
Telefono
617-370-8837
Indirizzo
60 HAMPSHIRE STREET, CAMBRIDGE
Confronta RLAY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RLAY
Relay Therapeutics Inc
|
6.51 | 1.04B | 25.55M | -341.97M | -304.44M | -2.80 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-09-04 | Ripresa | Guggenheim | Buy |
2025-04-17 | Iniziato | Wells Fargo | Equal Weight |
2024-09-10 | Ripresa | Goldman | Buy |
2024-09-10 | Aggiornamento | Jefferies | Hold → Buy |
2024-09-10 | Downgrade | Oppenheimer | Outperform → Perform |
2024-05-10 | Aggiornamento | Barclays | Equal Weight → Overweight |
2023-04-20 | Aggiornamento | Jefferies | Underperform → Hold |
2023-04-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
2023-04-13 | Iniziato | Raymond James | Outperform |
2023-02-03 | Iniziato | Oppenheimer | Outperform |
2022-09-30 | Iniziato | Barclays | Equal Weight |
2022-09-02 | Iniziato | Stifel | Buy |
2022-06-06 | Iniziato | Jefferies | Underperform |
2022-02-01 | Iniziato | Berenberg | Buy |
2021-07-21 | Iniziato | BofA Securities | Buy |
2020-12-15 | Reiterato | H.C. Wainwright | Buy |
2020-12-08 | Iniziato | JMP Securities | Mkt Outperform |
2020-11-05 | Iniziato | H.C. Wainwright | Buy |
2020-08-10 | Iniziato | Cowen | Outperform |
2020-08-10 | Iniziato | Goldman | Buy |
2020-08-10 | Iniziato | Guggenheim | Buy |
2020-08-10 | Iniziato | JP Morgan | Neutral |
Mostra tutto
Relay Therapeutics Inc Borsa (RLAY) Ultime notizie
Relay Therapeutics Inc.’s volatility index tracking explainedQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
Will Relay Therapeutics Inc. stock benefit from green energy trends2025 Key Highlights & High Conviction Investment Ideas - newser.com
Multi asset correlation models including Relay Therapeutics Inc.Portfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Key metrics from Relay Therapeutics Inc.’s quarterly dataMarket Risk Summary & Expert Verified Movement Alerts - newser.com
Wall Street Analysts Believe Relay Therapeutics (RLAY) Could Rally 116.91%: Here's is How to Trade - sharewise.com
Candlestick signals on Relay Therapeutics Inc. stock todayBond Market & Community Shared Stock Ideas - newser.com
Using Bollinger Bands to evaluate Relay Therapeutics Inc.2025 Risk Factors & Daily Chart Pattern Signals - newser.com
What MACD and RSI say about Relay Therapeutics Inc.Weekly Stock Summary & Smart Money Movement Alerts - newser.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Relay Therapeutics Inc. stock prediction for this weekEntry Point & Weekly High Potential Alerts - newser.com
Relay Therapeutics (NASDAQ:RLAY) Trading Up 7.5%Should You Buy? - MarketBeat
Can trapped investors hope for a rebound in Relay Therapeutics Inc.July 2025 Opening Moves & Capital Protection Trade Alerts - newser.com
Can a trend reversal in Relay Therapeutics Inc. lead to recoveryMarket Risk Report & Capital Efficiency Focused Ideas - newser.com
Short interest data insights for Relay Therapeutics Inc.July 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Is Relay Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Gains Summary & Smart Investment Allocation Tips - newser.com
Does Relay Therapeutics Inc. qualify in momentum factor screening2025 Volatility Report & Weekly High Momentum Picks - newser.com
Is Relay Therapeutics Inc. stock poised for growth2025 Price Momentum & Reliable Entry Point Trade Alerts - newser.com
Is Relay Therapeutics Inc. stock bottoming outWatch List & Free Verified High Yield Trade Plans - newser.com
Relay Therapeutics, Inc. $RLAY Shares Sold by Voya Investment Management LLC - Defense World
Is Relay Therapeutics Inc a good long term investmentPrice Action Analysis & Affordable Market Trading - earlytimes.in
What analysts say about Relay Therapeutics Inc stockPrice Action Analysis & Affordable Market Growth - earlytimes.in
Relay Therapeutics (NASDAQ:RLAY) Shares Up 7%Time to Buy? - MarketBeat
Institutional scanner results for Relay Therapeutics Inc.July 2025 Short Interest & Weekly High Conviction Trade Ideas - newser.com
Relay Therapeutics (NASDAQ:RLAY) Trading 7.9% HigherTime to Buy? - MarketBeat
Relative strength of Relay Therapeutics Inc. in sector analysisTrade Signal Summary & Safe Entry Zone Identification - newser.com
Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608 - Yahoo Finance
Acadian Asset Management LLC Buys 653,081 Shares of Relay Therapeutics, Inc. $RLAY - MarketBeat
Goldman Sachs Group Inc. Sells 627,974 Shares of Relay Therapeutics, Inc. $RLAY - MarketBeat
Relay Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Relay Therapeutics Inc Azioni (RLAY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Relay Therapeutics Inc Azioni (RLAY) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Rahmer Peter | See remarks |
Jul 28 '25 |
Sale |
3.74 |
1,359 |
5,083 |
393,722 |
Catinazzo Thomas | Chief Financial Officer |
Jul 29 '25 |
Sale |
3.68 |
18,380 |
67,638 |
335,295 |
Catinazzo Thomas | Chief Financial Officer |
Jul 28 '25 |
Sale |
3.74 |
1,701 |
6,362 |
353,675 |
Bergstrom Donald A | President, R&D |
Jul 29 '25 |
Sale |
3.68 |
26,701 |
98,260 |
552,720 |
Bergstrom Donald A | President, R&D |
Jul 28 '25 |
Sale |
3.74 |
4,069 |
15,218 |
579,421 |
Adams Brian | Chief Legal Officer |
Jul 29 '25 |
Sale |
3.68 |
18,276 |
67,256 |
371,472 |
Adams Brian | Chief Legal Officer |
Jul 28 '25 |
Sale |
3.74 |
1,637 |
6,122 |
389,748 |
Patel Sanjiv | President and CEO |
Jul 09 '25 |
Sale |
3.57 |
61,379 |
219,123 |
765,288 |
Rahmer Peter | See remarks |
Apr 30 '25 |
Sale |
3.00 |
10,739 |
32,217 |
390,081 |
Rahmer Peter | See remarks |
Apr 28 '25 |
Sale |
3.17 |
1,364 |
4,324 |
400,820 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):